Bioatla, Inc. (BCAB)
NASDAQ:BCAB
Want to see BCAB full AI Analyst Report?
BCAB Stock Chart & Stats
$0.19
-$0.03(-5.55%)
At close: 4:00 PM EST
$0.19
-$0.03(-5.55%)
Day’s Range― - ―
52-Week Range$3.92 - $71.50
Previous CloseN/A
Volume775.41K
Average Volume (3M)39.06K
Market Cap
$7.09M
Enterprise Value$4.11M
Total Cash (Recent Filing)$7.12M
Total Debt (Recent Filing)$6.20M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-50.50
Shares Outstanding1,659,612
10 Day Avg. Volume67,895
30 Day Avg. Volume39,059
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.92
Price to Sales (P/S)16.70
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue2.05
Enterprise Value/Gross Profit2.05
Enterprise Value/Ebitda-0.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary CAB PlatformBioAtla’s CAB technology offers tumor‑selective antibody activation that meaningfully differentiates therapeutics by aiming to reduce systemic toxicity. This structural platform advantage supports durable product differentiation, higher clinical utility, and stronger licensing/partnership optionality through development stages.
Modest Reported Debt LevelsReported absolute debt levels are low, limiting near‑term interest and leverage pressure. With minimal traditional debt burden, the company retains structural flexibility to pursue non‑debt financing or asset transactions during a strategic review, reducing insolvency risk from borrowing obligations.
Formal Strategic Review To Monetize AssetsManagement initiated a deliberate strategic review to monetize assets, pursue licensing, or complete transactions. This structural pivot can generate non‑dilutive capital, extend runway, and focus development spend on highest‑value programs, materially altering funding needs and long‑term program prioritization.
Bears Say
Negative Stockholders' EquityNegative shareholders’ equity reflects cumulative losses and a materially weakened balance sheet, reducing financial flexibility and complicating capital raises. This structural deficit can trigger covenant or listing issues, push reliance onto dilutive financing or asset sales, and deter counterparties long term.
Persistent Negative Cash FlowConsistent annual negative operating and free cash flow requires ongoing external capital to fund operations and trials. Even with improved burn, this durable cash‑gap pressures strategic choices, increases dilution risk, and limits ability to independently advance late‑stage development without partners or asset monetization.
Listing Risk & Deep RestructuringA ~70% workforce cut, leadership turnover, and an ongoing Nasdaq listing review are structural governance and execution risks. They reduce internal R&D capacity, can delay trials, and raise counterparty doubts, while listing uncertainty impairs access to public capital and long‑term investor confidence.
BioAtla News
BCAB FAQ
What was Bioatla, Inc.’s price range in the past 12 months?
Bioatla, Inc. lowest stock price was $3.92 and its highest was $71.50 in the past 12 months.
What is Bioatla, Inc.’s market cap?
Bioatla, Inc.’s market cap is $7.09M.
When is Bioatla, Inc.’s upcoming earnings report date?
Bioatla, Inc.’s upcoming earnings report date is May 13, 2026 which is in 9 days.
How were Bioatla, Inc.’s earnings last quarter?
Bioatla, Inc. released its earnings results on Mar 31, 2026. The company reported -$8 earnings per share for the quarter, beating the consensus estimate of -$12 by $4.
Is Bioatla, Inc. overvalued?
According to Wall Street analysts Bioatla, Inc.’s price is currently Overvalued.
Does Bioatla, Inc. pay dividends?
Bioatla, Inc. does not currently pay dividends.
What is Bioatla, Inc.’s EPS estimate?
Bioatla, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioatla, Inc. have?
Bioatla, Inc. has 1,659,612 shares outstanding.
What happened to Bioatla, Inc.’s price movement after its last earnings report?
Bioatla, Inc. reported an EPS of -$8 in its last earnings report, beating expectations of -$12. Following the earnings report the stock price went down -16.398%.
Which hedge fund is a major shareholder of Bioatla, Inc.?
Currently, no hedge funds are holding shares in BCAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioatla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Technical Analysis
Actinium Pharmaceuticals
―
―
Lantern Pharma
―
Century Therapeutics
―
MAIA Biotechnology, Inc.
―
Ownership Overview
Currently, No data available
---